Kimberly A. Curseen was named director of the Palliative Medicine Program at Winship Cancer Institute of Emory University.
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
